S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer

This study has been terminated.
(closed due to lack of availability of vaccine)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
First received: December 10, 2003
Last updated: July 20, 2012
Last verified: July 2012

RATIONALE: Vaccines made from a person's tumor tissue may make the body build an immune response to kill tumor cells.

PURPOSE: This phase II trial is studying vaccine therapy to see how well it works in treating patients with stage IIIB or stage IV bronchoalveolar (lung) cancer.

Condition Intervention Phase
Lung Cancer
Biological: GVAX lung cancer vaccine
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)

Resource links provided by NLM:

Further study details as provided by Southwest Oncology Group:

Primary Outcome Measures:
  • Progression-free and overall survival [ Designated as safety issue: No ]
  • Response rate [ Designated as safety issue: No ]
  • Toxicity [ Designated as safety issue: Yes ]
  • Functional status [ Designated as safety issue: No ]
  • Correlation of systemic biologic activity with clinical outcome [ Designated as safety issue: No ]

Enrollment: 19
Study Start Date: March 2004
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: treatment
GVAX lung cancer vaccine
Biological: GVAX lung cancer vaccine
6-7 injections per week in rotating locations for five weeks
Other Name: CG8123

Detailed Description:


  • Determine the progression-free and overall survival of patients with selected stage IIIB or stage IV bronchoalveolar carcinoma treated with GVAX lung cancer vaccine.
  • Determine the response rate (confirmed and unconfirmed and complete and partial) in patients treated with this vaccine.
  • Determine the frequency and severity of toxic effects of this vaccine in these patients.
  • Determine the functional status of patients treated with this vaccine.
  • Correlate systemic biologic activity (i.e., antigen-specific antitumor and systemic cytokine responses) with clinical outcome in patients treated with this vaccine.

OUTLINE: This is a multicenter study. Patients are stratified according to prior systemic cancer therapy for bronchoalveolar carcinoma (BAC) (yes vs no) and pattern of BAC (diffuse vs nodular).

After successful vaccine manufacturing from tumor tissue procured, patients receive GVAX lung cancer vaccine intradermally (ID) (6-7 injections per vaccination) on weeks 1, 3, 5, 7, and 9 for a total of 5 vaccinations. Treatment continues in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline and at weeks 9, 13, and 21.

Patients are followed at 4 weeks, every 8 weeks for 1 year, and then every 12 weeks for 2 years.

PROJECTED ACCRUAL: A total of 117 patients (67 previously untreated and 50 previously treated) will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Diagnosis* of 1 of the following by radiological features and clinical presentation:

    • Bronchoalveolar carcinoma (BAC)

      • Diffuse or ground glass appearance
    • Adenocarcinoma with bronchoalveolar features
    • BAC with focal invasion NOTE: *Histological confirmation (excluding fine needle aspiration or bronchial brushings or washings) is required after the tumor tissue has been procured and the vaccine has been produced
  • Selected stage IIIB (due to malignant pleural effusion) OR stage IV disease
  • Measurable or nonmeasurable disease (e.g., diffuse infiltrative process) by CT scan of the chest both before and after tumor tissue procurement for vaccine
  • Not a candidate for curative resection
  • Tumor accessible for tissue procurement via thoracentesis or a surgical procedure

    • If a pleural effusion is the source of tumor tissue, at least 600 mL of fluid must be available for vaccine manufacture
    • Resection of brain metastases may be used for vaccine processing

      • Surgery must be done after study entry
  • Asymptomatic previously treated (e.g., surgical resection or radiotherapy) brain metastases allowed provided the patient is neurologically stable
  • No active or impending spinal cord compression or evidence of pericardial tamponade



  • Over 18

Performance status

  • Zubrod 0-1

Life expectancy

  • Not specified


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • CD4 count greater than 200/mm^3
  • No bleeding disorder


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN) (3 times ULN if liver metastases are present)
  • SGOT or SGPT no greater than 2.5 times ULN (5 times ULN if liver metastases are present)
  • Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN if bone metastases are present)


  • Not specified


  • See Disease Characteristics
  • Patients requiring surgery for tumor tissue procurement must meet the following criteria:

    • Pulmonary artery systolic pressure < 40 mm Hg by echocardiogram*
    • LVEF > 40%
  • No symptomatic congestive heart failure
  • No thrombolic disorder
  • No unstable angina pectoris
  • No cardiac arrhythmia NOTE: *Not needed if patient has no tricuspid regurgitation


  • No pulmonary hypertension
  • No significant baseline hypoxia (i.e., O_2 saturation less than 90% OR requires greater than 2 L/min of supplemental O_2 via nasal cannula) by an oxygen saturation test
  • No postobstructive pneumonia
  • Patients requiring thoracoscopic surgery or thoracotomy for tumor tissue procurement must meet the following criteria:

    • Alveolar partial pressure of CO_2 < 45 mm Hg
    • Predicted postresection FEV_1 ≥ 1.0 L
    • DLCO > 50% of predicted


  • No active immune or autoimmune disease
  • No systemic lupus erythematosus
  • No sarcoiditis
  • No rheumatoid arthritis
  • No glomerulonephritis
  • No vasculitis
  • No serious infection
  • No hypersensitivity to any of the following:

    • Sargramostim (GM-CSF)
    • Pentastarch
    • Gentamicin
    • Human serum albumin
    • Dimethyl sulfoxide
    • Porcine trypsin
    • Fetal bovine serum
    • Recombinant benzonase
    • Other components of the vaccine or CG6444 adenoviral vector used in this study


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No poor nutritional status
  • No psychiatric illness or social situation that would preclude study compliance or increase operative risk
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission
  • No other concurrent uncontrolled illness


Biologic therapy

  • More than 4 weeks since prior biologic therapy
  • No prior gene therapy, including adenoviral-based therapy


  • More than 4 weeks since prior chemotherapy

    • No prior regional chemotherapy administered through the pulmonary artery (if resection of the tumor in the treated lobe is planned)

Endocrine therapy

  • More than 14 days since prior systemic corticosteroids
  • No concurrent steroids


  • See Disease Characteistics
  • More than 4 weeks since prior radiotherapy

    • Disease must be outside the areas of prior radiotherapy OR clear progression at prior irradiated sites must be documented
  • No prior radiotherapy to the tumor mass targeted for resection


  • See Disease Characteristics
  • More than 7 days since prior surgery and recovered


  • More than 2 weeks since prior epidermal growth factor receptor inhibitors
  • No other concurrent nonprotocol-specified treatment
  • No concurrent immunosuppressants
  • No concurrent chronic anticoagulation therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00074295

Sponsors and Collaborators
Southwest Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Angela Davies, MD University of California, Davis
Principal Investigator: Raja Mudad, MD, FACP Tulane University Health Sciences Center
  More Information

Responsible Party: Southwest Oncology Group
ClinicalTrials.gov Identifier: NCT00074295     History of Changes
Other Study ID Numbers: CDR0000343797  U10CA032102  S0310 
Study First Received: December 10, 2003
Last Updated: July 20, 2012
Health Authority: United States: Federal Government
United States: Food and Drug Administration

Keywords provided by Southwest Oncology Group:
bronchoalveolar cell lung cancer
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
recurrent non-small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Lung Diseases
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016